InterMune Inc. (ITMN) saw a big move last session, as the company’s shares fell by nearly 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for ITMN, as the stock is now down almost 36% since Jan 16.
The biotechnology company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (4 increases, 2 decreases), and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.
ITMN currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the biotech sector include Actelion Ltd. (ALIOF), Alexion Pharmaceuticals, Inc. (ALXN) and Affymetrix Inc. (AFFX). While Actelion and Alexion carry a Zacks Rank #1 (Strong Buy), Affymetrix holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
INTERMUNE INC (ITMN): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
(ALXN): Free Stock Analysis Report
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
Zacks Investment Research